MedX Health Corp. Announces Granting of Stock Options - Jan. 17, 2020

Logo
Jan. 17, 2020 03:37 UTC

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), dedicated to the early detection of skin cancer, announces that a total of 5,990,000 stock options have been granted to directors (2,020,000 options), Officers (1,580,000 options) and employees and consultants (2,390,000 options). The options are all exercisable at the price of $0.17 per share, valid for a period to December 31, 2024, and vest immediately. The Company notes that a total of 7,150,000 stock options previously granted in 2014 expired unexercised on November 26, 2019. At this time there are a total of 21,200,000 options available for grant under the Company’s Incentive Stock Option Plan, of which a total of 17,765,000 are currently subject to grants, at a weighted average exercise price of $0.197, and 3,435,000 remain available for grant under the Plan.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its SIAScopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005914/en/

Contacts

Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229

 

Source: MedX Health Corp.

Back to news